Today marked a milestone moment for Sironax. We celebrated recent transformative achievements – the strategic expansion of our US team and IND approvals from China CDE. These are pivotal steps that position us to accelerate global development while staying root-ed in groundbreaking science.
At Sironax, we tackle the hardest problems in degenerative diseases. We are deeply proud of our team’s relentless pursuit of innovation, having successfully advanced several FIC/BIC candidates into clinical development. Standing at this turning point, we’re closer than ever to a future where once-inevitable diseases are no longer a threat, and disease-modifying ther-apies transform lives of millions of patients and their families.
“The future is not written—it is ours to create.”
With a strengthened global footprint and a pipeline of FIC/BIC assets, we’re poised to rede-fine what’s possible.
About Sironax
Headquartered in Waltham, Massachusetts, Sironax is a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunologic, metabolic, and rare diseases. The company has built a diverse pipeline of programs by targeting contributors of aging: degeneration, metabolic dysfunction, and inflammation. In addition to NAMPT activator SIR4156, Sironax is conducting clinical studies with SARM1 inhibitor SIR2501 and RIPK1 inhibitor SIR9900, as well as ongoing preclinical research. The company was recently named to Fierce Biotech’s “Fierce 15” list of the most innovative and promising private biotechs of 2026. For more information, visit sironax.com.